Dr. Reddy’s Laboratories has launched Toripalimab, marketed as Zytorvi®, in India, establishing the country as the third globally to access this cutting-edge immuno-oncology drug. Approved by major regulatory bodies like the USFDA, EMA, and DCGI, Toripalimab is the first and only treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). It has demonstrated a 48% reduction in the risk of disease progression or death when combined with standard chemotherapy.
India, among the top five nations burdened by NPC, recorded over 6,500 cases in 2022, with high prevalence in northeastern states. In Mizoram, where cancer rates are significantly above the national average, this launch holds particular promise. Access to advanced therapies like Toripalimab could transform cancer care in the region, enabling better outcomes for patients facing limited treatment options.
M.V. Ramana, CEO of Branded Markets, highlighted the launch as a milestone in oncology innovation. “Toripalimab addresses a critical need for Indian patients, offering a superior alternative to existing therapies and reinforcing our commitment to making innovative cancer care accessible,” he said.
+ There are no comments
Add yours